美国癌症联合委员会第九版胃神经内分泌瘤分期系统更新要点及解读

Key updates and interpretation of the ninth version of AJCC staging system for neuroendocrine tumors of the stomach

美国癌症联合委员会(AJCC)肿瘤分期系统是临床应用最广泛的肿瘤分期依据。2023年10月,AJCC发布了第九版胃神经内分泌瘤分期系统,并于2024年1月开始应用实施。第九版胃神经内分泌瘤分期系统主要在组织病理分型、诊断和分期方法、临床及病理分期、预后分级、肿瘤及非肿瘤因素预后特征等方面进行了更新。分期系统的更新及推行对胃神经内分泌瘤的准确诊断、分期和精准治疗提供了更详细的参考依据,便于临床医师进行临床实践。本文结合相关循证医学证据对胃神经内分泌瘤新版分期的重要更新进行阐述解读。

The cancer staging system of the American Joint Committee on Cancer(AJCC)is the most widely used clinical basis for tumor staging.In October 2023,AJCC released the staging system(ninth version)for the neuroendocrine tumors of stomach(NET),which has been implemented in January 2024.The ninth version of NET staging system mainly updated the histopathologic classification,diagnosis and staging methods,clinical and pathological staging,prognosis grade,tumor and non-tumor prognostic features.The update and implementation of the staging system provide a more detailed reference for the accurate diagnosis,staging and precise treatment of gastric neuroendocrine tumors.Moreover,it is convenient for clinicians to carry out clinical practice.The purpose of our article is to provide a high-level overview of the major changes in AJCC staging system(version 9)for gastric NET based on the latest evidence-based medical research.